Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting
Abstract Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse o...
Saved in:
| Main Authors: | Qiling Bu, Hong-Hu Zhu, Wenming Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01681-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans
by: Margherita Romeo, et al.
Published: (2025-07-01) -
A Case of Primary Amyloidosis Involving Liver, Stomach, Intestines, and Heart without Evident Kidney Involvement
by: L. S. Kholopov, et al.
Published: (2022-03-01) -
Cardiac amyloidosis in the practice of a cardiologist and therapist. Case report
by: T. V. Nikiforova, et al.
Published: (2025-01-01) -
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation
by: Gréta Garami, et al.
Published: (2025-01-01) -
An atypical cause of amyloidosis: a case of combined heavy and light chain amyloidosis
by: Dina R. Gonzalez-Hernandez, et al.
Published: (2025-07-01)